Keywords: delay, eu, approval, gsk, tyverb, ec, considers

Delay to EU approval of GSK

Article | 31 March 2008

Print This

European approval of UK drug major GlaxoSmithKline's oral breast cancer drug Tyverb (lapatinib) will be delayed while regulators consider new ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in